CROI* 2009 CME/CE Talking Slides Update Assessing Best Practices in HIV/AIDS Therapy Complete CME/CE Program Details

HIV and AIDS Articles

Comparison of HAART Outcomes among HIV Positive Children in Developing and Developed Countries Elevated Rate of Heart Attacks and Strokes in HIV Patients on HAART Begins to Decline at California Kaiser Permanente Does Efavirenz Cause Lipid Accumulation in the Liver? Risk Factors for Immune Reconstitution Inflammatory Syndrome after Starting Antiretroviral Therapy Viral Load "Blips" Linked to Kidney Dysfunction, Role of Tenofovir Remains Unclear Interim IMPAACT Results Show Raltegravir (Isentress) Is Safe and Effective for Children and Adolescents with HIV HDL Cholesterol -- but not LDL -- Predicts Cardiovascular Events in SMART Treatment Interruption Trial Nicotine Replacement Aids Smoking Cessation in Program for HIV Positive Participants International Health Agencies Launch Web Clearinghouse for Information on Circumcision for HIV Prevention Treatment Intensification with Raltegravir (Isentress) Does Not Eradicate Residual HIV Lopinavir/ritonavir (Kaletra) Monotherapy May Be Hazardous for Patients with a History of Low CD4 Cell Counts NNRTI Microbicide UC781 Appears Safe for Rectal Use Does Breastfeeding Negatively Affect the Health and Survival of HIV Positive Mothers? WHO CD4 Cell Criteria May Lead to Unnecessary Antiretroviral Therapy Changes in Resource-limited Settings Data from Multiple Studies -- D:A:D, ANRS CO4, ALLRT, STEAL, HEAT -- Fail to Resolve Abacavir (Ziagen) Cardiovascular Risk Issue Cancer Incidence in Clinical Trials of Raltegravir (Isentress) HIV Can Remain in Semen despite Effective Antiretroviral Therapy HIV Positive People Can Modify Several Risk Factors that Increase Mortality Immune Deficiency Linked to Non-AIDS-defining Cancers with Infectious Causes Large Meta-analysis Indicates Antiretroviral Therapy Works as Well for Women as for Men Switching from Lopinavir/ritonavir (Kaletra) to Raltegravir (Isentress) Leads to Poorer HIV Suppression, but Better Lipid Profiles: SWITCHMRK Diabetes Drug Rosiglitazone (Avandia) Improves Limb Fat Loss in HIV Patients on Antiretroviral Therapy Hormonal Contraceptives Do Not Accelerate Disease Progression in HIV Positive Women CDC Researchers Present Analysis of People with Undiagnosed HIV Infection in the U.S. Two Large Cohort Studies Do Not Resolve Question of When to Start Antiretroviral Treatment ESPRIT and SILCAAT Studies Find No Long-term Benefits of IL-2 HIV Infection Increases the Risk of Atherosclerosis as Much as Traditional Risk Factors Pre-exposure Prophylaxis Using Oral or Vaginal Tenofovir plus Emtricitabine Protects Monkeys from SIV Infection Two New Pharmaco-enhancers -- GS-9305 and SPI-452 -- May Rival Ritonavir (Norvir) as a Boosting Agent Experimental Anti-HIV Gel Shows Promise in Large-scale Study in Women Conference on Retroviruses and Opportunistic Infections Starts Sunday in Montreal

HIV-HCV and HIV-HBV Coinfection Articles

Studies Look at Liver Fibrosis in HIV-HCV and HIV-HBV Coinfected People Studies from Europe and the U.S. Provide Further Information on Sexual Transmission of Hepatitis C Virus among HIV Positive Men Uninterrupted HAART, more than Hepatitis C Treatment, Predicts Survival in HIV-HCV Coinfected Patients Antiretroviral Treatment Interruption May Affect HCV Viral Load, HBV Rebound, and Liver Fibrosis Progression in Coinfected Patients High HCV Viral Load Is Associated with an Increased Risk of Death in HIV-HCV Coinfected Individuals British Study Finds HIV-HCV Coinfected Patients Do Not Have Impaired CD4 Cell Recovery after Starting HAART Long-term Tenofovir (Viread) Leads to Improvement of Liver Fibrosis in HIV-HBV Coinfected Patients Liver-related Deaths among People with HIV May Be Decreasing Due to Declining Hepatitis C Prevalence Low CD4s, Interferon Therapy, and Hepatitis Delta Impair Health-related Quality of Life for HIV-HBV Coinfected Patients Adequate Ribavirin Level Promotes Sustained Response to Interferon-based Therapy for HIV-HCV Coinfected Patients HIV-HCV Coinfected Women May Experience More Pegylated Interferon and Ribavirin Side Effects than Men Does Telbivudine (Tyzeka) Have Activity Against HIV? HIV-HCV Coinfected Patients Experience Longer Hospitalization, More Emergency Visits, and Greater Disability than People with HIV Alone Despite Infrequent "Blips," Tenofovir (Viread) Provides Good Hepatitis B Virus Suppression HIV-HBV Coinfected Individuals Complete Early Response to Pegylated Interferon/ribavirin Predicts Sustained Response in HIV-HCV Coinfected Patients: SLAM-C Human Genetic Variation Associated with Good T-cell Response Predicts Successful Treatment in HIV-HCV Coinfected Patients

Library of Slides and Posters

Characterization of an Outbreak of Acute Hepatitis C Virus Infection in HIV-infected Men in New York City D Fierer and others. CROI 2009. In Vivo Viral Dynamics and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and Abacavir (ABC): Evidence of a Non-Additive Antiviral Effect M Goicoechea and others. CROI 2009. Copyright GlaxoSmithKline. Used with permission 2009. Similar Reductions in Markers of Inflammation and Endothelial Activation after Initiation of Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) in the HEAT Study G McComsey and others. CROI 2009. Copyright GlaxoSmithKline. Used with permission 2009. Assessment of Renal Findings of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FTC) in Combination with QD Lopinavir/Ritonavir (LPV/r) Over 96 Weeks in the HEAT Study D Finek and others. CROI 2009. Copyright GlaxoSmithKline. Used with permission 2009. Changes in Bone Turnover, OPG/RANKL, and Inflammation with ART Initiation: A Comparison of Tenofovir- and Non-Tenofovir-Containing Regimens T Brown and others. CROI 2009. Copyright GlaxoSmithKline. Used with permission 2009. Characterization of virologic failures in the randomized, controlled, Phase III ARTEMIS trial in treatment-naïve patients (Week 96 analysis) I Dierynck and others. CROI 2009. Preclinical and Early Clinical Evaluation of SPI-452, a New Pharmacokinetic Enhancer (PKE) S Gulnik and others. CROI 2009. Factors affecting virologic response to darunavir/ritonavir and lopinavir/ritonavir in treatment-naïve HIV-1-infected patients in ARTEMIS at 96 weeks M Nelson and others. CROI 2009. Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive C Königs and others. CROI 2009. A Pilot Study to Determine the Effect on Dyslipidemia of the Addition of Tenofovir to Stable ART in HIV-infected Subjects: Results from A5206 Study Team M Tungsiripat and others. CROI 2009. In Vivo Viral Dynamics and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and Abacavir (ABC): Evidence of a Non-Additive Antiviral Effect M Goicoechea and others. CROI 2009. Single Dose Tenofovir Disoproxil Fumarate (TDF) with and without Emtricitabine (FTC) in HIV-1 Infected Pregnant Women and Their Infants: Pharmacokinetics (PK) and Safety P Flynn and others. CROI 2009. Structural Basis for HIV-1 Reverse Transcriptase Drug Resistance to Zidovudine (AZT) and Tenofovir K Das and others. CROI 2009. Lack of Minority K65R Resistant Viral Populations Detected after Repeated Interruptions of Tenofovir DF/ Zidovudine/Lamivudine A Joyce and others. CROI 2009. Viral Resistance to the HIV-1 Integrase Inhibitor GS-9160 G Jones and others. CROI 2009. Phenotypic Susceptibility to Bevirimat Among HIV-Infected Patient Isolates Without Prior Exposure to Bevirimat N Margot and others. CROI 2009. No Evidence for Decay in the Latent Reservoir in HIV-infected Patients Receiving Intensive Enfuvirtide (ENF)-containing Antiretroviral Therapy R Gandhi and others. CROI 2009. GS-9350: A Pharmacoenhancer WithoutAnti-HIV Activity A Mathias, and others. CROI 2009. High Resolution Crystallographic Analysis of the Competitive Binding of a Novel Nucleotide Analog GS-9148-Diphosphate to HIV-1 Reverse TranscriptaseEB S Lanson and others. CROI 2009. Comparison of Phenotypic (Trofile®) and Genotypic (SensiTrop II) Assays to Determine HIV Tropism in Treatment-Naïve Subjects M McCarthy and others. CROI 2009. Comparison of Trofile® and ViroTectTropism Assays in Treatment-Experienced Subjects R Vilchez and others. CROI 2009. HIV Testing and Monitoring in Privately Insured Members Recently Diagnosed with Potential AIDS Defining Events Y Chen and others. CROI 2009.

15th Conference on Retroviruses and Opportunistic Infections (CROI 2009)
Coverage by HIV and Hepatitis.com - February 8 - 11, 2009, Montreal
HIV and AIDS Treatment News, Experimental News, FDA-approved News

Highlights of the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2009) - Coverage by HIV and Hepatitis.com, February 8 - 11, 2009, Montreal